A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Previous studies showed that patients with early TNBC with increased CDK4/6 and ERK activity are at high risk of relapse. Preclinical data also suggest the benefit of combined inhibition of CDK4/6 and MEK, and novel therapies are needed for TNBC in the advanced disease setting. Despite the rationale and a biomarker-driven design, this combination was toxic and showed limited efficacy. This combination should not be further developed in this disease.
Authors
- Miguel Quintela-Fandiño (ORCID: https://orcid.org/0000-0003-1648-1964)
- Juan Miguel Cejalvo (ORCID: https://orcid.org/0000-0002-8755-8626)
- José Á. García-Sáenz (ORCID: https://orcid.org/0000-0001-6880-0301)
- Lucía González Cortijo (ORCID: https://orcid.org/0000-0003-2082-670X)
- Luís Manso (ORCID: https://orcid.org/0000-0002-1683-550X)
- Silvana Mourón (ORCID: https://orcid.org/0000-0001-6287-8001)
- Rodrigo Sánchez-Bayona (ORCID: https://orcid.org/0000-0002-5255-6620)
- Leonardo D. Garma (ORCID: https://orcid.org/0000-0003-1220-8397)
- María J. Bueno (ORCID: https://orcid.org/0000-0002-3910-0637)
- Alfonso Cortés (ORCID: https://orcid.org/0000-0003-3006-7583)
- Serafin M. Morales (ORCID: https://orcid.org/0000-0001-7445-4193)
- Juan Antonio Guerra (ORCID: https://orcid.org/0000-0003-1295-8008)
Institutions
- Hospital Universitari Arnau de Vilanova (ES)
- Hospital Clínico San Carlos (ES)
- Spanish National Cancer Research Centre (ES)
- Hospital Clínico Universitario de Valencia (ES)
- Hospital Universitario 12 De Octubre (ES)
- Hospital Universitario Quirónsalud Madrid (ES)
- Hospital Arnau de Vilanova (ES)
- Hospital Universitario de Fuenlabrada (ES)
- INCLIVA Health Research Institute (ES)
- Hospital Universitario Ramón y Cajal (ES)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0428
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca
- Eisai
- Instituto de Salud Carlos III